Excellergy
Manufacturing · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
3000 El Camino Real Bldg 4 Ste 200, Palo...Website
www.excellergy.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Excellergy
Excellergy is a biotechnology company developing a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases and help improve patient quality of life.Explore more
Excellergy Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Excellergy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Excellergy launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Excellergy had a recent Job posting/layoffs
Excellergy, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Excellergy has new funding data
Check out if Excellergy is spiking on competitors!
Check if Excellergy has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Excellergy recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Excellergy
Recommended Actions
Reach out to Masked Content who joined Excellergy as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Excellergy is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Excellergy is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Excellergy.
Excellergy financials insights
Gather financial insights about Excellergy, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Series A
$70M
Excellergy Tech Stack
A closer look at the technologies used by Excellergy
Excellergy News & Media
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
March 27 () - Swiss drugmaker Novartis said on Friday it will buy California-based biotech company Excellergy in a deal worth up to $2 billion, the second sizeable acquisition it has announced in as many weeks. Under the agreement, Novartis said it would pay up to $2 billion in upfront and milestone payments.Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience Basel, March 27, 2026 – Novartis today announced that it has entered into an agreementExcellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial
Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Excellergy
Sign Up For FreeTo access detailed company insights
Excellergy is a biotechnology company developing a first-in-class portfolio of trifunctional effector cell response inhibitors (ECRIs) to combat severe allergic diseases and help improve patient quality of life.... Read More
